Takeda Oncology 1Point and VRAP/VPAP Programs

Patient Support Services Guide 2018

1Point Patient Services
Velcade Reimbursement Assistance Program
Ariad Pass

Takeda Oncology 1Point program offers comprehensive services that can assist patients with the financial burden and other day-to-day needs associated with Ninlaro (ixazomib), Alunbrig (brigatinib), or Iclusig (ponatinib) treatment. Takeda Oncology 1Point program provides assistance for eligible patients with all insurance types through the Co‑Pay Assistance Program, the RapidStart Program, and the Patient Assistance Program.

The list of Takeda Oncology medications, their indications, and programs is provided in the Table.

Takeda Oncology also offers a suite of services and resources to practices and eligible patients seeking access to Velcade (bortezomib), including the Velcade Reimbursement Assistance Program (VRAP) and the Velcade Patient Assistance Program (VPAP).

Takeda Oncology 1Point Patient Services

  • Assisting eligible patients with out-of-pocket costs
  • Helping patients understand their insurance coverage for Ninlaro, Alunbrig, or Iclusig
  • Providing information about specialty pharmacies that can help patients get Ninlaro, Alunbrig, or Iclusig
  • Helping patients start therapy as quickly as possible, as directed by their physician
  • Connecting patients to additional resources, such as legal services, counseling and support programs, emotional support, and transportation assistance.

VRAP and VPAP Patient Services

  • Financial assistance
  • Navigation through reimbursement processes and concerns
  • Referrals to independent copay foundations
  • Support and resources for the insured, uninsured, and underinsured.


Co-Pay Assistance Program

Patients with private insurance who may have difficulties paying for Ninlaro, Alunbrig, or Iclusig may be eligible for the Co-Pay Assistance Program. For patients prescribed Ninlaro, this savings program covers out-of-pocket expenses of >$25 for a monthly prescription, and for patients prescribed Alunbrig or Iclusig, this program covers out-of-pocket expenses of >$10 for a monthly prescription, with a maximum benefit of $25,000 annually. The copay card can be renewed every 12 months.

Patients are not eligible to participate if their prescription is covered by any federal or state healthcare program, including Medicare, Medicaid, TRICARE, or Medicare Part D; or insurance that is paying the entire cost of the prescription.

RapidStart Program

Patients prescribed Ninlaro may be eligible to receive a free 1-cycle (28-day) supply if they are experiencing a delay in insurance coverage of ≥7 business days. Other eligibility criteria include:

  • An appropriate diagnosis for Ninlaro for an FDA-approved indication
  • A new prescription for Ninlaro
  • Having Medicare Part D or commercial insurance coverage.

This program also provides a free 30-day supply of Alunbrig or Iclusig to patients with a delay in insurance coverage of ≥5 days. Patients may be eligible to enroll if they:

  • Are prescribed Alunbrig or Iclusig for an FDA-approved indication
  • Have insurance coverage.

Takeda Oncology Patient Assistance Program

The Patient Assistance Program offers free monthly supplies of Ninlaro, Alunbrig, or Iclusig to patients who have no insurance or are underinsured. Eligibility depends on the number of members in the household and the annual gross household income. Patients must have a valid prescription for Ninlaro, Alunbrig, or Iclusig and must provide household income verification.

Velcade Reimbursement Assistance Program

VRAP is available to all patients receiving Velcade, regardless of their financial and insurance situations. Enrollment in VRAP provides access to a case manager to share support options and resources to facilitate therapy. For more information visit this website.

Velcade Patient Assistance Program

Patients residing in the United States who have no insurance coverage for Velcade may be eligible to participate in VPAP. Eligibility is based on the treatment setting, household income, US residency, and a prescription for the FDA-approved use of Velcade.

Application & Enrollment

Takeda Oncology 1Point

Enrollment in the Ninlaro 1Point program requires physicians and patients to complete the Ninlaro 1Point enrollment form and faxing it to 844-269-3038.

Enrollment forms for Alunbrig 1Point and Iclusig 1Point are available online, and can either be faxed to the number or mailed to the address listed on the respective form.

Patient health insurance information and verification of income are also required. Takeda Oncology 1Point will contact the physician’s office once the benefit verification is complete and will provide patients with a summary of benefits within 2 business days of the receipt of all required information.

Enrollment in the Takeda Oncology 1Point Co-Pay Assistance Program is also medication-specific. Patients prescribed Ninlaro can enroll online or by calling 844-617-6468; patients prescribed Alunbrig can enroll online or by calling 844-217-6468; and those prescribed Iclusig can enroll by calling 844-817-6468.

After patients have enrolled, they will receive a letter in the mail from Takeda Oncology 1Point containing their copay card.

Patients interested in participating in the RapidStart Program should notify their physicians so that they can complete the RapidStart section of the Ninlaro 1Point enrollment form.

Patients interested in participating in the Patient Assistance Program should first complete the 1Point enrollment form and then the drug-specific Patient Assistance Program Application with their physician.

The application for the following drugs are available online: Alunbrig | Iclusig | Ninlaro

If the patient is approved for this program, the patient and his or her physician will be notified and a 1-month supply of the medication will be mailed to the patient.

Each month, the physician’s office must confirm that the patient is still being treated with Ninlaro, Alunbrig, or Iclusig and requires another month’s supply of the drug. Eligible patients can be enrolled for up to 1 year.


Enrollment in VRAP requires the completion of the enrollment form, and faxing it to 800-891-9843, or mailing it to the address on the form.

Patients need to coordinate with their healthcare provider to complete this form to include the diagnosis (including the diagnosis code), route of administration, the patient’s previous therapies, and the clinical service setting. The patient’s health insurance information and verification of income are also required.

The specific requested service(s) should be indicated on the VRAP enrollment form. Patients are eligible to participate in VPAP for 1 year, as long as they continue to meet the program’s qualifications. They can re-enroll after 12 months if they continue to use Velcade.

Table Takeda Oncology Drugs

Patient support programs

Alunbrig (brigatinib) tablets
Metastatic non–small-cell lung cancer with ALK in patients whose disease progressed during, or are intolerant of, crizotinib

Iclusig (ponatinib) tabletsa
Chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia; chronic myeloid leukemia with T315I mutation; Ph+ acute lymphoblastic leukemia with T315I mutation

Ninlaro (ixazomib)
Multiple myeloma, in combination with lenalidomide and dexamethasone

Velcade (bortezomib)
Multiple myeloma; mantle-cell lymphoma

Ph+ indicates Philadelphia chromosome–positive.
aIclusig was previously covered under the ARIAD Pass program.